Private capital has poured into fusion startups, lifting total funding from $10 billion to $15 billion within months. Investors ranging from biotech‑focused VCs to SpaceX‑style funds now treat the sector as a distinct asset class, even though a commercial reactor remains decades away. On TechCrunch’s Equity podcast, DCVC partner Rachel Slaybaugh explains why the money rush feels more like “fusion euphoria” than a traditional venture cycle.

Slaybaugh notes the investment thesis mirrors biotech, hinging on a measurable Q‑value threshold that signals net‑energy gain. Leading firms are closing in on that figure, a milestone that could unlock public‑market valuations. Meanwhile, advances in superconducting tape and AI‑driven plasma modeling are delivering incremental progress, often eclipsed by breakthroughs. A surprise merger between a fusion startup and Trump Media sparked bewildered reactions across the sector.

For investors, the shift means allocating capital on longer horizons, akin to biotech pipelines rather than quick exits. As startups edge toward the Q‑value target, valuation models will likely transition from speculative to revenue‑linked, giving limited partners clearer exit pathways. The sector’s rapid cash infusion shows markets are finally willing to bet on fusion’s eventual payoff.